AR128463A1 - Uso de un agonista del receptor de melanocortina-4 en la prevención o el tratamiento de obesidades genéticas raras - Google Patents

Uso de un agonista del receptor de melanocortina-4 en la prevención o el tratamiento de obesidades genéticas raras

Info

Publication number
AR128463A1
AR128463A1 ARP230100283A ARP230100283A AR128463A1 AR 128463 A1 AR128463 A1 AR 128463A1 AR P230100283 A ARP230100283 A AR P230100283A AR P230100283 A ARP230100283 A AR P230100283A AR 128463 A1 AR128463 A1 AR 128463A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
rare genetic
pharmaceutically acceptable
obesities
Prior art date
Application number
ARP230100283A
Other languages
English (en)
Spanish (es)
Inventor
Hee Dong Park
Hye Kyeong Hwang
Su Jin Yeo
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR128463A1 publication Critical patent/AR128463A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP230100283A 2022-02-08 2023-02-07 Uso de un agonista del receptor de melanocortina-4 en la prevención o el tratamiento de obesidades genéticas raras AR128463A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20220016377 2022-02-08

Publications (1)

Publication Number Publication Date
AR128463A1 true AR128463A1 (es) 2024-05-08

Family

ID=87564659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100283A AR128463A1 (es) 2022-02-08 2023-02-07 Uso de un agonista del receptor de melanocortina-4 en la prevención o el tratamiento de obesidades genéticas raras

Country Status (13)

Country Link
US (1) US20250134898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4461297A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505229A (cg-RX-API-DMAC7.html)
KR (1) KR20230120106A (cg-RX-API-DMAC7.html)
CN (1) CN119300835A (cg-RX-API-DMAC7.html)
AR (1) AR128463A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023218785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248118A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002389A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024011882A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024009854A (cg-RX-API-DMAC7.html)
TW (1) TWI838114B (cg-RX-API-DMAC7.html)
WO (1) WO2023153762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202315A1 (en) * 2020-12-22 2022-06-30 Hee Dong Park Use as selective agonist of malanocortin-4 receptor
KR20250046623A (ko) * 2023-09-27 2025-04-03 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
US12516047B2 (en) * 2019-11-07 2026-01-06 Lg Chem, Ltd. Melanocortin-4 receptor agonists
CN116507615A (zh) * 2020-10-29 2023-07-28 株式会社Lg化学 黑皮质素受体激动剂化合物的晶型i及其制备方法
TWI804170B (zh) * 2021-01-21 2023-06-01 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑的用途
TWI826938B (zh) * 2021-02-26 2023-12-21 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑
TWI861780B (zh) * 2022-03-28 2024-11-11 南韓商Lg化學股份有限公司 預防或治療肥胖的聯合療法

Also Published As

Publication number Publication date
JP2025505229A (ja) 2025-02-21
AU2023218785A1 (en) 2024-08-22
CA3248118A1 (en) 2025-01-24
WO2023153762A1 (ko) 2023-08-17
EP4461297A4 (en) 2025-04-09
CL2024002389A1 (es) 2025-01-31
TW202339761A (zh) 2023-10-16
CN119300835A (zh) 2025-01-10
CO2024011882A2 (es) 2025-01-23
TWI838114B (zh) 2024-04-01
EP4461297A1 (en) 2024-11-13
US20250134898A1 (en) 2025-05-01
KR20230120106A (ko) 2023-08-16
MX2024009854A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
DOP2020000058A (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
RU2009137607A (ru) Композиции и наборы для лечения гриппа
MX2010007375A (es) Nuevos derivados de lupano.
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
DOP2024000088A (es) Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
MX2025005933A (es) Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il)butan-2-il)benzamida como inhibidores de la proteasa para el tratamiento o la prevencion de la infeccion por coronavirus
GEAP202516765A (en) Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
CO2024011882A2 (es) Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidad
CO2025004701A2 (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
DOP2022000107A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
CO2024002712A2 (es) Azálidos inmunomoduladores
MX2023008098A (es) Uso de agonista del receptor de melanocortina-4.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AR122450A1 (es) Compuestos de (trifluorometil)pirimidin-2-amina
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
MX2022014461A (es) Nuevos abridores de canales de potasio maxi-k para el tratamiento de trastornos asociados con x fragil.
AR134364A1 (es) Compuestos antivirales de indolinilo y sus usos
AR133526A1 (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
JP2019515025A5 (cg-RX-API-DMAC7.html)
AR127582A1 (es) Métodos para el tratamiento del cáncer